Farmas USA

Te mando un privi @anaramos ;)

SNTA

Tengo una duda, según veo aquí (que no se si es verdadero o falsificado):

http://yahoo.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=9145293-904-9466&SessionID=QCdKF6MVEdrRPl7

El señor/a Vukovik Vojo, que es Chief Medical Officer de SNTA, compró 100.000 acciones el 3 de mayor a 9,65$

¿Esto es así? ¿es compra de insider o venta? ¿de ser cierta la compra, es tonto? ¿hay algo raro?

Yo es que soy gilipollas y he ampliado posición en 6,96$ y no se si estar acojonado, o que...

SNTA

Es una compra pero es del 5 de marzo. La fecha en inglés va al revés (3/5/2013). Claro que, si no las ha vendido, es una buena noticia y probablemente relacionada con los resultados del ensayo :D

Voy a comprobar los forms...

Cuidado! que son fechas americanas!

ES 3 DE MARZO

y hay multiples compras insider de entonces
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001179110%2D13%2D004595%2Etxt&FilePath=%5C2013%5C03%5C07%5C&CoName=SYNTA+PHARMACEUTICALS+CORP&FormType=4&RcvdDate=3%2F7%2F2013&pdf=

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001179110%2D13%2D004591%2Etxt&FilePath=%5C2013%5C03%5C07%5C&CoName=SYNTA+PHARMACEUTICALS+CORP&FormType=4&RcvdDate=3%2F7%2F2013&pdf=

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001179110%2D13%2D004592%2Etxt&FilePath=%5C2013%5C03%5C07%5C&CoName=SYNTA+PHARMACEUTICALS+CORP&FormType=4&RcvdDate=3%2F7%2F2013&pdf=

Entorno a MEDIO MILLON DE SHARES adquiridas en 9,65

3 de marzo, 4 abril, 5 mayo, 6 junio, 7 julio San Fermín......iros a dormir que mañana rebota.

Steven Rosenman y su ultimo comentario

http://seekingalpha.com/instablog/1282351-steve-rosenman/1838181-price-target-update-for-amarin-amrn#comments_header

Changing my 2013 view for Amarin price target from $28-32 to $34 by May 2014 as company is well positioned to achieve NCE from FDA, be given Anchor indication approval on or before December 20, 2013; latest intel suggests the company is in very late stage discussions with third parties on how to proceed with launching Anchor.

Additionally, Marine launch seems to be going as forecasted. I do not believe we have a VVUS situation here and management likely to confirm slow, but steady and positive trend on 5/9 investor conference call. There could be slight, non-material upside or downside to the expected revenues generated over the past 3 months from Marine, but the launch seems to be trending as any new small pharma company launch would-- slow to start, with increasing scripts.

I believe FDA has given important clues over the past 2 months of how NCE will be treated, the company may know "when". A possible update on the conference call, but more likely this front will remain quiet, in the best interest of AMRN-FDA dealings.

Conference call likely to revolve (from management's point of view) around expected demand for Anchor and favorable supply and patent position. CC likely to revolve (from analyst and investor perspective) on strategic path for anchor launch.

AMRN

SNTA

Formularios comprobados y encima descubro varios más de varias personas de las mismas fechas y, entre ellos, Ramachandra Suman, el director de I+D que ha dimitido.

Y no consta que nadie haya vendido. ¿No es bonito? :D

http://ir.syntapharma.com/phoenix.zhtml?c=147988&p=irol-secText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTg3OTYwMzgmRFNFUT0xJlNFUT0mU1FERVNDPVNFQ1RJT05fSU5TSURFUiZleHA9JnN1YnNpZD01Nw%3d%3d

MODO MALDITO EXPEDIENTE X ON

Bonito y precioso mientras las ventas no se produjeran ayer y hoy y mañana tengamos los filing registrados

;)